Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for LTI-03 in Idiopathic pulmonary fibrosis. The expected timing is based on the latest available company guidance and may change.
RENEW trial. 5/1/24- Positive Cohort 1 Ph1b data. 9/23/24 Cohort 2 enrollment complete. 11/13/24- Topline data reported. 5/12/25- Initiated Ph2. 5/27/25- First patient dosed. 11/3/25- Clinical hold lifted. Restart enrollment in late 2025 or early 2026. Initial topline data in Q3 2026. 01/20/26:- EMA granted orphan drug designation for IPF, supporting LTI-03 development alongside ongoing Ph2 trial. 03/03/26:- First patient dosed in Ph2 after FDA clearance. Interim data anticipated in H2 2026. Enrollment expected through Mid-2027. 04/29/26:- RENEW Ph2 enrolled 8 patients; enrollment began March 2026; more sites opening soon. 05/18/26:- Financing closed; expects to fund RENEW Ph2 through completion; cash runway into Q1 2028. 06/11/26:- RENEW Ph2 enrolled 16 patients; first patient randomized in the U.K. 07/21/26:- RENEW Ph2 enrolling in five countries; initial topline data expected in H2 2026. 08/14/26:- RENEW Ph2 surpassed 25% enrollment. Interim data will be reported in H2 2026. 08/20/26:- FDA granted Fast Track for IPF. RENEW Ph2 interim data still expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.